Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

The recruitment status of this study is unknown because the information has not been verified recently.

Verified March 2007 by Groupe Francophone des Myelodysplasies.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Groupe Francophone des Myelodysplasies

ClinicalTrials.gov Identifier:

NCT00443339

First received: March 4, 2007

Last updated: May 15, 2007

Last verified: March 2007

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	July 2008
Estimated Primary Completion Date:	No date given

No publications provided by Groupe Francophone des Myelodysplasies

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Adès L, Pillard F, Lambert C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, Béné MC, Rose C, Dreyfus F, Fenaux P. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol. 2013 May;92(5):621-31. doi: 10.1007/s00277-013-1686-4. Epub 2013 Jan 29.

To Top